Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases

Bram Verstockt(Universitair Ziekenhuis Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Jonas Dehairs(KU Leuven), Séverine Vermeire(KU Leuven), Kaline Arnauts(Rega Institute for Medical Research), Azucena Salas(Hospital Clínic de Barcelona), Gert Van Assche(KU Leuven), Gert De Hertogh(KU Leuven), Sare Verstockt(KU Leuven), Marisol Veny(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Clinical Gastroenterology and Hepatology
August 22, 2019
10.1016/j.cgh.2019.08.030
Cited by 77

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k